2. Legend Biotech (NASDAQ:LEGN)
Upside Potential: 219.6%
Legend Biotech (NASDAQ: LEGN) ranks second in our list of biotechnology stocks with more than 50% upside potential, and the company has emerged as a major player in the rapidly expanding field of cell therapy for cancer treatment. The company specializes in developing CAR-T therapies designed to harness the body’s immune system to attack cancer cells more effectively.
The company’s flagship therapy, Carvykti, has already established itself as an important treatment option for patients with multiple myeloma. However, analysts believe the therapy’s long-term growth potential may extend even further as clinical trials explore its use in earlier stages of the disease.
RBC Capital analyst Leonid Timashev recently reaffirmed his Outperform rating on the stock while setting a price target of $66. His analysis was influenced by updated guidance from the U.S. Food and Drug Administration regarding accelerated approval endpoints in multiple myeloma clinical trials. The FDA’s support for using minimal residual disease negativity and complete response rates as approval metrics could potentially shorten development timelines for therapies like Carvykti.
Raymond James analysts also reiterated their bullish outlook, highlighting the strong clinical data supporting the therapy and the expanding commercial opportunity in multiple myeloma treatment. As cell therapy technologies continue evolving, Legend Biotech remains one of the companies positioned to benefit from the growing adoption of advanced immunotherapy treatments.
Click next to see the following stock...
